1.25

0.81% 0.01

Lava Therapeutics Nv (LVTX)

Overview News Price History Option Chain Discussions Forecast

Lava Therapeutics Nv stock is traded at $1.25, with a volume of 6,353. It is up +0.81% in the last 24 hours and down -1.57% over the past month. LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.

Previous Close:

$1.24

Open:

$1.22

24h Volume:

6,353

Relative Volume:

0.02

Market Cap:

$34.46M

Revenue:

$9.06M

Net Income/Loss:

$-50.39M

P/E Ratio:

-0.651

EPS:

-1.92

Net Cash Flow:

$5.89M

1W Performance:

-4.58%

1M Performance:

-1.57%

6M Performance:

-34.21%

1Y Performance:

-59.68%

1-Day Range:

$1.22

$1.28

1-Week Range:

$1.20

$1.33

52-Week Range:

$0.8502

$3.20

Lava Therapeutics Nv Stock (LVTX) Company Profile

Name

Lava Therapeutics Nv

Sector

Healthcare (1153)

Industry

Biotechnology (662)

Phone

31 6 3000 3035

Address

YALELAAN 62, UTRECHT

Employee

Twitter

Next Earnings Date

2025-03-28

Latest SEC Filings

LVTX's Discussions on Twitter

Compare LVTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LVTX Lava Therapeutics Nv	1.25	34.46M	9.06M	-50.39M	5.89M	-1.92
VRTX Vertex Pharmaceuticals Inc	501.59	126.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	609.53	65.06B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	649.86	37.54B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	259.85	32.56B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	255.97	26.40B	3.81B	-644.79M	-669.77M	-6.24

Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-12-24	Downgrade	Leerink Partners	Outperform → Market Perform
Dec-11-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Oct-25-22	Initiated	H.C. Wainwright	Buy
Apr-19-21	Initiated	JP Morgan	Overweight
Apr-19-21	Initiated	Jefferies	Buy
Apr-19-21	Initiated	SVB Leerink	Outperform

View All

Lava Therapeutics Nv Stock (LVTX) Latest News

Apr 16, 2025

LAVA Therapeutics Strengthens Balance Sheet with $5.1 Million Repayment Waiver from Netherlands Enterprise Agency - Nasdaq

Apr 16, 2025

Lava Therapeutics Granted Full Waiver For RVO Payment Obligation - marketscreener.com

Apr 16, 2025

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation - GlobeNewswire

Apr 16, 2025

LAVA Therapeutics Strengthens Balance Sheet: Secures Complete Waiver of $5.1M Debt - Stock Titan

Apr 16, 2025

Apr 06, 2025

Investors Aren't Buying LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Revenues - simplywall.st

Apr 06, 2025

Apr 01, 2025

Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads after asset cut - Investing.com India

Apr 01, 2025

LAVA Therapeutics (NASDAQ:LVTX) Receives Neutral Rating from HC Wainwright - Defense World

Apr 01, 2025

Mar 31, 2025

Leerink cuts Lava Therapeutics stock target to $1 By Investing.com - Investing.com Canada

Mar 31, 2025

Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads after asset cut By Investing.com - Investing.com South Africa

Mar 31, 2025

Leerink cuts Lava Therapeutics stock target to $1 - Investing.com

Mar 31, 2025

JMP maintains LAVA Therapeutics stock Market Perform rating By Investing.com - Investing.com Australia

Mar 31, 2025

JMP maintains LAVA Therapeutics stock Market Perform rating - Investing.com

Mar 31, 2025

Mar 28, 2025

Lava Therapeutics Reports 2024 Financial Results - TipRanks

Mar 28, 2025

LAVA Therapeutics NV earnings beat by $0.16, revenue topped estimates - Investing.com Australia

Mar 28, 2025